<DOC>
	<DOCNO>NCT00471237</DOCNO>
	<brief_summary>This 12 month study design evaluate safety effectiveness SB-751689 treatment osteoporosis post-menopausal woman , comparison 2 active comparators placebo .</brief_summary>
	<brief_title>A Phase II Study Evaluating SB-751689 Post-Menopausal Women With Osteoporosis .</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Inclusion : Informed consent : Subject willing able provide write informed consent . Menopausal status : Ambulatory female age &lt; 80 year screen &gt; 5 year postmenopausal . TScore : A subject either one prevalent vertebral fracture eligible inclusion satisfy one follow Tscore requirement : If prevalent vertebral fracture subject must absolute BMD value consistent Tscore le equal 2.5 great 4.0 either femoral neck , total hip , trochanter , lumbar spine , If one prevalent vertebral fracture subject must absolute BMD value consistent Tscore le equal 2.0 great 4.0 either femoral neck , total hip , trochanter , lumbar spine . Suitable vertebra : Two vertebra range L1 L4 suitable BMD measurement DXA . Protocol compliance : Subject , opinion investigator , willing able comply requirement protocol . Exclusion : TScore : Has absolute BMD value consistent Tscore le equal 4.0 either femoral neck , total hip , trochanter , lumbar spine . Vertebral fracture : Has &gt; 1 prevalent vertebral fracture screen visit . Nonvertebral fracture : Any previous nonvertebral osteoporosis related/fragility fracture age 40 . Spine deformity : Significant spine deformity would preclude DXA/QCT assessment . BMI : BMI ≥33kg/m2 . Bone metabolic disease : Other osteoporosis , history concurrent diseases affect bone metabolism ( e.g. , osteomalacia , hyperparathyroidism , hyperthyroidism ) . GI disease : History major upper gastrointestinal disease Malabsorption : Active history malabsorption ( e.g. , history celiac disease , irritable bowel syndrome inflammatory bowel disease ) . Liver disease : Past current history liver disease know hepatic biliary abnormality , ( exception previously document diagnosis Gilbert 's syndrome ) . Rheumatoid arthritis : Active disease history rheumatoid arthritis . Nephrolithiasis : History active nephrolithiasis ( kidney stone ) . Osteosarcoma risk : Subjects increase risk osteosarcoma Paget 's disease bone prior external beam implant radiation therapy involve skeleton . Malignancy : Malignant disease diagnose within previous 5 year ( except resect basal cell cancer ) . Biological abnormality : Any clinically relevant biological abnormality find and/or volunteer screening ( related disease investigation ) , opinion investigator , clinically significant would preclude safe participation study . Surgical medical condition : Presence follow condition within six month prior screen : myocardial infarction , coronary bypass surgery , coronary artery angioplasty , unstable angina , cardiac arrhythmia , clinically evident congestive heart failure , cerebrovascular accident . Glomerular filtration rate : Glomerular filtration rate ( GFR ) &lt; 35 mL/min calculate Modification Diet Renal Disease ( MDRD ) equation follow : GFR ( mL/min/1.73 m2 ) = 186 x ( Serum creatinine mg/dL ) 1.154 x ( Age ) 0.203 x ( 0.742 female ) x ( 1.210 African American ) ( conventional unit ) . QT/QTc prolongation : A marked baseline prolongation QT/QTc interval ( e.g. , QTc interval ≥450 msec Screening ECG ) . Torsades de Pointes : A history risk factor Torsades de Pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) . Liver chemistry : Liver chemistry [ aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) total bilirubin ] exceed 2fold upper limit laboratoryspecified reference range , screen . Abnormal serum calcium : Serum calcium ( total albuminadjusted ) outside central laboratory reference range screen visit . Abnormal PTH : PTH ( intact whole ) outside normal range . Abnormal creatine phosphokinase : Creatine phosphokinase ( CPK ) outside normal range . Abnormal alkaline phosphatase : Alkaline phosphatase outside normal range . Thyroid hormone replacement : Subjects receive thyroid hormone replacement therapy must TSH level check . Subjects exclude TSH level &lt; 0.1 &gt; 10.0mIU/L . However , subject exclude TSH range 0.14.5 mIU/L . If TSH &gt; 4.5 ≤10.0mIU/mL , measure T4 exclude subject T4 outside normal range . Vitamin D deficiency : Vitamin D deficiency ( serum 25hydroxy vitamin D &lt; 20ng/mL , equivalent 50nmol/L ) screening . Subjects undergo vitamin D repletion per local practice rescreened vitamin D level within 6week screening period . They remain excluded rescreened value &lt; 20ng/mL . Previous strontium IV bisphosphonate : Any previous treatment strontium ranelate intravenous bisphosphonate . Oral bisphosphonates : Any previous treatment oral bisphosphonate follow : treatment within last six month one month cumulative treatment within last 12 month three month cumulative treatment within past two year , two year cumulative treatment within past five year . Fluoride : Treatment fluoride ( dose great 10mg/day ) within previous 5 year osteoporosis . Digoxin : Current therapy digoxin . Bone metabolism drug : Treatment drug affect bone metabolism within last six month prior screen : Chronic systemic corticosteroid [ e.g. , glucocorticoid , mineralocorticoid ] treatment 2 intraarticular injection within past year use oral , parenteral , longterm , highdose inhaled corticosteroid . Treatment topical corticosteroid exclude subject participate . Hormones [ e.g. , estrogens/ '' natural estrogen preparation '' ( except nonsystemic vaginal treatment ) , 19norprogestins , SERMs raloxifene , anabolic steroids/androgens dehydroepiandrosterone ( DHEA ) sulfate form ( DHEAS ) , nandrolone , tibolone , active vitamin D analogs/metabolites 1,25dihydroxy vitamin D ( calcitriol ) 1alphahydroxyvitamin D3 ( 1alpha hydroxycholecalciferol ) , calcitonin ] . Calcineurin inhibitor [ e.g. , cyclosporine , tacrolimus ] methotrexate . Previous anabolic agent : Treatment PTH , PTH analogues similar anabolic agent osteoporosis within last two year . Contraindications : Contraindications therapy calcium vitamin D. Pregnancy : Women pregnant allow study . Interfering medication : Vitamin A excess 10,000 IU per day , heparin , lithium , anticonvulsant medication except benzodiazepine . Investigational drug exposure : Administration investigational drug within 90 day precede first dose study drug . Substance abuse : History current evidence drug alcohol abuse within previous 12 month . Problems swallow : Inability swallow tablet whole . The following exclusion criterion apply subject allocate openlabel teriparatide group : Calcium channel blocker : Current therapy calcium channel blocker diltiazem verapamil . Oral Azole Antifungals : Current therapy oral azole antifungal . Immunosuppressants : Current therapy cyclosporine oral tacrolimus . Ritonavir : Current therapy ritonavir . Quinidine : Current therapy quinidine . Macrolide Antibiotics : Subjects anticipate require chronic use macrolide antibiotic . Alendronate Contraindications : Contraindications therapy alendronate . Additional Exclusion Criteria Subjects Recruited QCT Sites Hip surgery : History hip surgery result metal implant either leave right side would cause artefact QCT scan . Additional Exclusion Criteria Teriparatide Subjects Teriparatide contraindication : Contraindications therapy teriparatide accord locally approve datasheet .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>bone mineral density ,</keyword>
	<keyword>Ronacaleret</keyword>
	<keyword>teriparatide</keyword>
	<keyword>alendronate ,</keyword>
	<keyword>Post-menopausal woman ,</keyword>
	<keyword>osteoporosis ,</keyword>
	<keyword>SB-751689</keyword>
</DOC>